WO2022049977A1 - 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法 - Google Patents
中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法 Download PDFInfo
- Publication number
- WO2022049977A1 WO2022049977A1 PCT/JP2021/028948 JP2021028948W WO2022049977A1 WO 2022049977 A1 WO2022049977 A1 WO 2022049977A1 JP 2021028948 W JP2021028948 W JP 2021028948W WO 2022049977 A1 WO2022049977 A1 WO 2022049977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mesenchymal stem
- stem cells
- nervous system
- central nervous
- serum
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 33
- 238000009472 formulation Methods 0.000 title abstract description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 152
- 239000012679 serum free medium Substances 0.000 claims abstract description 61
- 210000001258 synovial membrane Anatomy 0.000 claims abstract description 40
- 206010008118 cerebral infarction Diseases 0.000 claims description 36
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 29
- 208000020431 spinal cord injury Diseases 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 19
- 238000012258 culturing Methods 0.000 claims description 14
- 238000007710 freezing Methods 0.000 claims description 14
- 230000008014 freezing Effects 0.000 claims description 14
- 239000003761 preservation solution Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000010257 thawing Methods 0.000 claims description 7
- 238000005138 cryopreservation Methods 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000003387 muscular Effects 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 67
- 241000700159 Rattus Species 0.000 description 30
- 238000000034 method Methods 0.000 description 28
- 239000002609 medium Substances 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 21
- 238000011156 evaluation Methods 0.000 description 20
- 239000007640 basal medium Substances 0.000 description 14
- 210000003141 lower extremity Anatomy 0.000 description 14
- 206010060860 Neurological symptom Diseases 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000007659 motor function Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 239000003978 infusion fluid Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 5
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102100031168 CCN family member 2 Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- -1 ascorbic acid compound Chemical class 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 208000013677 cerebrovascular dementia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000010726 hind limb paralysis Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
Definitions
- the present invention relates to a composition for treating a central nervous system disease, a method for producing a composition for treating a central nervous system disease, a method for producing a therapeutic formulation for a central nervous system disease, and a method for preserving a therapeutic formulation for a central nervous system disease.
- central nervous system disease Diseases caused by abnormalities or damage to the central nervous system such as the brain or spinal cord, such as cerebral infarction, head trauma, spinal cord injury, cerebrovascular dementia, Alzheimer's disease and Parkinson's disease (hereinafter, also referred to as "central nervous system disease”).
- central nervous system disease As the treatment of.), Oral or injectable medication or surgical treatment is performed.
- these treatments are symptomatic treatments, and treatment methods for central nervous system diseases have not been sufficiently established.
- Mesenchymal stem cells should be isolated not only from tissues such as bone marrow, fat, synovial, alveolar bone and periodontal ligament, but also from various tissues such as placenta, umbilical cord blood and umbilical cord. Can be done.
- mesenchymal stem cells can also be cultured and proliferated in vitro.
- mesenchymal stem cells can differentiate into non-mesenchymal cells (eg, neural progenitor cells and hepatocytes) as well as mesenchymal cells (eg, osteoblasts, adipose cells and chondrocytes). Since it has pluripotency, it is expected to be used as a raw material for producing cells used in regenerative medicine or cell therapy.
- Mesenchymal stem cells are cultured using a serum-containing medium such as fetal bovine serum (FBS).
- FBS fetal bovine serum
- This serum is used as a nutrient source for promoting cell growth or proliferation in vitro, or as a source of a physiologically active substance such as a hormone.
- FBS fetal bovine serum
- a method using a serum-free medium containing no serum can be mentioned.
- Patent Documents 1 to 3 describe serum-free cultures used for culturing mesenchymal stem cells.
- mesenchymal stem cells are diverse, and the functions of mesenchymal stem cells currently in use are some of them. Therefore, it is expected to develop a new therapeutic approach using mesenchymal stem cells for diseases such as central nervous system diseases. What kind of mesenchymal stem cells are suitable for the treatment of central nervous system diseases? Was unknown.
- One aspect of the present invention is to provide a composition for treating a central nervous system disease, including mesenchymal stem cells, which is suitably used for the treatment of a central nervous system disease.
- synovial membrane-derived mesenchymal stem cells cultured in serum-free medium were used as mesenchymal stem cells cultured in serum medium. They have found that they have significantly higher efficacy against central nervous system diseases (for example, immunomodulatory effect, anti-inflammatory effect, angiogenic effect and neuroprotective effect) than those of mesenchymal stem cells, and have completed the present invention.
- one embodiment of the present invention has the following configuration.
- the therapeutic composition for central nervous system diseases of the present invention is characterized by containing synovial-derived mesenchymal stem cells cultured in a serum-free medium.
- the method for producing a therapeutic composition for central nervous system disease of the present invention is characterized by comprising a step of culturing synovial membrane-derived mesenchymal stem cells in a serum-free medium.
- mesenchymal stem cells derived from the synovial membrane cultured in a serum-free medium are suspended in a storage solution for freezing, and the obtained suspension is used. It is characterized by comprising a cryopreservation step of freezing and a step of thawing the suspension and diluting the suspension so that the mesenchymal stem cells have a concentration suitable for administration.
- the mesenchymal stem cells constituting the therapeutic composition for the central nervous system of the present invention are specified in a manufacturing process such as "cultured in a serum-free medium".
- the present inventors have different expression levels between the mesenchymal stem cells used in the present invention and conventional mesenchymal stem cells (specifically, mesenchymal stem cells cultured in a serum medium). Tests were performed for the presence of genes (in other words, gene markers). As a result, it was clarified that the expression levels of a huge variety of genes differed, but any of these genes was used between the mesenchymal stem cells used in the present invention and the conventional mesenchymal stem cells. It was not possible to identify whether it was important for the distinction.
- compositions for treating a central nervous system disease containing mesenchymal stem cells which is suitably used for the treatment of a central nervous system disease.
- FIG. 1 It is a figure which shows the outline of the procedure of the evaluation method which concerns on Example 1.
- FIG. It is a figure which showed the result of having measured the neurological symptom score in Example 1.
- FIG. It is a figure which showed the result of having measured the area of the total cerebral infarction lesion in Example 1.
- FIG. It is a figure which shows the outline of the procedure of the evaluation method which concerns on Example 2.
- FIG. It is a figure which showed the result of having measured the BBB score in Experimental Example 2-1 of Example 2.
- “serum-free medium” is intended to be a serum-free medium
- “serum-free culture” is intended to be a culture without serum.
- “mesenchymal stem cell” means a stem cell derived from a cell belonging to the mesenchymal system.
- those obtained by isolating mesenchymal stem cells having specific properties those in which some kind of stimulation such as cytokine stimulation is given to mesenchymal stem cells, and those in which a gene is introduced are also included.
- MUSE cells, MAPC cells and the like are also included.
- the mesenchymal stem cells are preferably human mesenchymal stem cells, but may be mesenchymal stem cells derived from non-human mammals such as rats and mice.
- the synovium is roughly classified into a fibrous synovium that covers the femur or the joint capsule in the joint and a fatty synovium of the subpatellar fat pad.
- "synovial-derived mesenchymal stem cells” are intended to be both fibrous synovial-derived mesenchymal stem cells and fatty synovial-derived mesenchymal stem cells.
- composition for treating a central nervous system disease is intended to be a drug having an effect of promoting recovery / regeneration of a central nervous system disease.
- Therapeutic compositions for central nervous system diseases are not only those using mesenchymal stem cells in their original state without changing their functions, but also by culturing and proliferating under specific conditions to secretorize and differentiate. It also includes those using cells with improved functions such as ability.
- Method for producing a composition for treating central nervous system diseases In the method for producing a composition for treating a central nervous system disease according to an embodiment of the present invention (hereinafter, also referred to as "the method for producing the present embodiment"), mesenchymal stem cells derived from the synovial membrane are used in a serum-free medium. It is a method including a step of culturing.
- the composition of the serum-free medium for culturing the synovial membrane-derived mesenchymal stem cells is not particularly limited, and a known composition of the serum-free medium can be appropriately used.
- the basal medium for constituting the serum-free medium is not particularly limited as long as it is a known medium for mammalian cells, and preferred basal media are, for example, Ham's F12 medium, DMEM medium, RPMI-1640 medium, MCDB. Examples include a medium. These basal media may be used alone or in combination of two or more.
- the basal medium for constituting the serum-free medium is preferably a medium in which MCDB and DMEM are mixed at a ratio of 1: 1.
- the basal medium is, for example, PDGF (Platelet-derived Growth Factor), EGF (Epidermal Growth Factor), TGF- ⁇ (Transforming Growth Factor- ⁇ ), HGF (Hepatocyte Growth Factor), at least one.
- PDGF Platinum-derived Growth Factor
- EGF Epidermal growth Factor
- TGF- ⁇ Transforming Growth Factor- ⁇
- HGF Hepatocyte Growth Factor
- a serum-free medium supplemented with phospholipids and at least one fatty acid may be used.
- the final concentration of PDGF in the basal medium is preferably 0.5 to 100 ng / mL, more preferably 10 ng / mL.
- the final concentration of EGF in the basal medium is preferably 0.5 to 200 ng / mL, more preferably 20 ng / mL.
- the final concentration of TGF- ⁇ in the basal medium is preferably 0.5 to 100 ng / mL, more preferably 10 ng / mL.
- the final concentration of HGF in the basal medium is preferably 0.1 to 50 ng / mL, more preferably 5 ng / mL.
- the total content of phospholipids in the basal medium is preferably 0.1 to 30 ⁇ g / mL, more preferably 10 ⁇ g / mL at the final concentration.
- the total fatty acid content with respect to the basal medium is preferably 1/1000 to 1/10 of the weight of the basal medium, and more preferably 1/100.
- the phospholipid to be added to the basal medium is not particularly limited, and is, for example, phosphatidic acid, lysophosphatidic acid, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine and phos.
- examples thereof include fatidylglycerol, and these phospholipids may be used alone or in combination (for example, in combination with phosphatidic acid and phosphatidylcholine).
- These phospholipids may be of animal origin or of plant origin.
- the fatty acid added to the basal medium is not particularly limited, and examples thereof include linoleic acid, oleic acid, linoleic acid, arachidonic acid, myristic acid, palmitic acid, palmitic acid, stearic acid, and the like, and these fatty acids are used alone. It may be used or may be used in combination. Further, the serum-free medium according to the present embodiment may further contain cholesterol in addition to the fatty acid.
- PDGF is intended to be a growth factor selected from the platelet-derived growth factor (PDGF) family, and is preferably PDGF-BB or PDGF-AB.
- EGF is intended to be a growth factor selected from the epidermal growth factor (EGF) family.
- the serum-free medium may further contain any one of connective tissue growth factor (Connective Tissue Growth Factor, CTGF), vascular endothelial growth factor (Vascular Endothelial Growth Factor, VEGF) and ascorbic acid compound.
- CTGF Connective Tissue Growth Factor
- VEGF vascular endothelial growth factor
- ascorbic acid compound ascorbic acid compound
- the ascorbic acid compound is intended to be ascorbic acid (vitamin C), ascorbic acid diphosphate, or a compound similar thereto.
- the serum-free medium may contain a lipid antioxidant, and examples of the lipid antioxidant include DL- ⁇ -tocopherol acetate (vitamin E). Further, the serum-free medium may further contain a surfactant, and examples of the surfactant include Pluronic (registered trademark) F-68 or Tween (registered trademark) 80.
- the serum-free medium may further contain insulin, transferrin, dexamethasone, serum albumin and serenate.
- insulin may be an insulin-like growth factor, derived from natural cells, or produced by genetic recombination. If the serum-free medium contains at least one of dexamethasone, insulin and serum albumin, it has the effect of prolonging the survival period of mesenchymal stem cells and enhancing the proliferation of mesenchymal stem cells.
- a known serum-free medium may be used as the serum-free medium in the production method of the present embodiment.
- Known serum-free media include, for example, STK (registered trademark) 1 (manufactured by TWOCELLS Co., Ltd.), STK (registered trademark) 2 (manufactured by TWOCELLS Co., Ltd.), and a complete synthetic medium kit for human mesenchymal stem cells (MSCGM-CD BulletKit).
- synovial membrane-derived mesenchymal stem cells isolated from animal tissues or cells such as humans by a conventionally known method are seeded and cultured in the above-mentioned serum-free medium.
- the culture conditions for example, it is preferable to inoculate synovial membrane-derived mesenchymal stem cells separated from 1 to 500 mg of tissue pieces (including mesenchymal stem cells) per 1 mL of medium, and the culture temperature is 37 ° C. ⁇ 1. It is preferably at ° C and under 5% CO 2 .
- the culturing time is not particularly limited as long as the culturing time reaches the target concentration of synovial membrane-derived mesenchymal stem cells.
- the culture time may be 1 to 5 hours, 1 to 10 hours, 1 to 20 hours, or 1 hour to 1 day. It may be 1 hour to 10 days, 1 hour to 30 days, 1 hour to 50 days, 30 hours to 70 hours, 40 hours. The time may be from 50 hours to 70 hours, or from 50 hours to 70 hours.
- the synovial membrane-derived mesenchymal stem cells used in the production method of the present embodiment are not particularly limited, but are collected from primary mesenchymal stem cells, that is, animal tissues such as humans, and then subcultured even once. It is preferable that the cells are not present.
- the culture vessel used for culturing is not particularly limited as long as the synovial membrane-derived mesenchymal stem cells can proliferate.
- a Falcon 75 cm 2 flask, a Sumitomo Bakelite 75 cm 2 flask, and the like can be preferably used.
- the proliferation of the cell may be affected by the type of culture vessel used. Therefore, in order to proliferate the mesenchymal stem cells more efficiently, each mesenchymal stem cell (hereinafter, also referred to as “proliferation target cell”) to be proliferated is cultured using a culture vessel suitable for proliferation. It is preferable to do.
- a method for selecting a culture vessel suitable for proliferation for example, a method for allowing cells to be grown to select the optimum culture vessel can be mentioned.
- multiple types of culture vessels are prepared, cells to be grown are grown under the same culture conditions except that the types of culture vessels are different, and the number of cells 2 weeks after the start of culture is measured by a known method.
- the culture vessel is suitable for the growth of the cells to be grown in order from the one having the largest number of cells.
- the growth target cells are grown in order from the one with the shortest period to reach 80 to 90% of the number of cells in the confluent state. It can be determined that the culture vessel is suitable.
- cell adhesion molecules include fibronectin, collagen, gelatin and the like.
- One type of these cell adhesion molecules may be used alone, or a plurality of types may be used in combination.
- the content of the cell adhesion molecule in the serum-free medium is preferably 1 to 50 ⁇ g / mL, more preferably 5 ⁇ g / mL at the final concentration.
- the efficiency of adhesion of cells to be grown to a culture vessel can be improved by adding fibronectin to a serum-free medium so that the final concentration of fibronectin is 5 ⁇ g / mL. can.
- mesenchymal stem cells may be passaged at least once. Since mesenchymal stem cells proliferate in a scaffold-dependent manner, when the mesenchymal stem cells are proliferating locally and unevenly, by substituting the mesenchymal stem cells during the proliferation of the mesenchymal stem cells, etc.
- the culture conditions can be improved.
- the method for subculturing mesenchymal stem cells is not particularly limited, and subculture can be performed using a conventionally known method for subculturing mesenchymal stem cells.
- Examples of the "cell release agent containing no components derived from mammals and microorganisms" include TrypLE Select (Life Technologies) and ACCUTASE (Innovative Cell Technologies, Inc.).
- composition for the treatment of central nervous system diseases is a membrane-derived mesenchymal stem cell cultured in a serum-free medium. Contains.
- the synovial membrane-derived mesenchymal stem cells contained in the therapeutic composition of the present embodiment are [1. It is a synovial-derived mesenchymal stem cell cultured in a serum-free medium described in the column of [Method for producing a composition for treating central nervous system diseases]. That is, the mesenchymal stem cells contained in the therapeutic composition of the present embodiment are synovial-derived mesenchymal stem cells proliferated in the above-mentioned method for producing a therapeutic composition for central nervous system disease.
- the therapeutic composition of the present embodiment has an effect of promoting recovery / regeneration of central nervous system diseases. It is known that mesenchymal stem cells have different differentiation potential and expression of secretory components depending on the tissues of origin such as bone marrow, adipose tissue and umbilical cord. We found that synovial-derived mesenchymal stem cells cultured in a serum-free medium have higher immunomodulatory effects, anti-inflammatory effects, and blood vessels than mesenchymal stem cells cultured in a serum-containing medium. It was found to have a neoplastic effect and a neuroprotective effect.
- the therapeutic composition of the present embodiment contains mesenchymal stem cells derived from synovium cultured without serum, an unknown pathogen (virus, pathogenic prion, etc.) contaminated in the serum is a patient. There is no risk of being administered into the body.
- serum since serum is very expensive and is a natural product, the components differ from lot to lot, so that the cell proliferation effect tends to vary.
- serum since serum is not used in the present invention, such a situation occurs. No problem occurs.
- it is not necessary to perform purification in order to remove serum-derived proteins and the like from the mesenchymal stem cells after culturing work efficiency can be improved.
- the therapeutic composition of the present embodiment is not particularly limited as a central nervous system disease for which an effect is exhibited.
- central nervous system diseases include, for example, cerebral infarction, cerebral hemorrhage, head injury, spinal cord injury, Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, Huntington's disease, multiple sclerosis and muscular atrophic lateral sclerosis. Can be mentioned.
- the therapeutic composition of the present embodiment may be a drug consisting of mesenchymal stem cells derived from the synovial membrane cultured in a serum-free medium, but other than mesenchymal stem cells cultured in a serum-free medium. May include pharmaceutically acceptable additives (eg, buffers, antioxidants, thickeners and excipients).
- pharmaceutically acceptable additives eg, buffers, antioxidants, thickeners and excipients.
- the amount of the additive is not particularly limited, but is, for example, 0.01 to 50% by weight, 0.01 to 40% by weight, 0.01 to 30% by weight, 0.01 of the therapeutic composition of the present embodiment. It can be from 20% by weight, 0.01 to 10% by weight, or 0.01 to 1% by weight.
- the number of mesenchymal stem cells contained in the therapeutic composition of the present embodiment is not particularly limited and can be appropriately set according to the body weight of the administration target.
- It can be 10 10 cells or 1 ⁇ 10 6 cells to 1 ⁇ 10 10 cells.
- Examples of the method for administering the therapeutic composition include intravenous injection, arterial injection and injection into a local area (spinal cord (for example, spinal cord cavity), muscle, joint, ventricle, etc.).
- a local area for example, spinal cord cavity
- muscle for example, spinal cord cavity
- ventricle etc.
- the method of administration to an artery in the vicinity of a local area using a catheter has an advantageous effect that the number of cells required for administration can be reduced.
- the administration target of the therapeutic composition of this embodiment is not particularly limited.
- the administration target may be human and non-human mammals (bovine, pig, sheep, goat). , Horses, dogs, cats, rabbits, mice, rats, etc.).
- the administration target may be the mammal, and the mammal such as human may be administered. It may be other than. That is, the mesenchymal stem cells of the therapeutic composition of the present embodiment may be transplanted into a heterologous animal or may be transplanted into an allogeneic animal. Transplantation into allogeneic animals may be autologous or allogeneic.
- the dose of the therapeutic composition of the present embodiment is not particularly limited, but the number of mesenchymal stem cells administered per 1 kg of the body weight of the subject to be administered is 1 ⁇ 10 2 cells to 1 ⁇ 10 9 cells, 1 ⁇ . 10 3 cells to 1 ⁇ 10 9 cells, 1 ⁇ 10 4 cells to 1 ⁇ 10 9 cells, 1 ⁇ 10 5 cells to 1 ⁇ 10 9 cells or 1 ⁇ 10 6 cells to 1 ⁇ 10 9 cells. obtain.
- the "drug for the treatment of central nervous system disease” is intended to be a pharmaceutical product having an effect of promoting recovery / regeneration of central nervous system disease, which is formulated so as to be in a state suitable for administration.
- the therapeutic formulation for central nervous system diseases is not only a formulation of mesenchymal stem cells in their original state without changing their functions, but also by culturing and proliferating under specific conditions, such as differentiation potential. It also includes the pharmaceutical product of cells with improved function.
- the synovial membrane-derived mesenchymal stem cells in the method for producing the therapeutic formulation of the present embodiment are [1. It is a synovial-derived mesenchymal stem cell cultured in a serum-free medium described in the column of [Method for producing a composition for treating central nervous system diseases]. That is, the synovial-derived mesenchymal stem cells in the method for producing a therapeutic preparation of the present embodiment are synovial-derived mesenchymal stem cells proliferated in the method for producing a therapeutic composition for central nervous system disease described above.
- mesenchymal stem cells derived from the synovial membrane cultured in a serum-free medium are suspended in a storage solution for freezing, and the obtained suspension is frozen. Includes storage step.
- the composition of the preservative solution for freezing the synovial membrane-derived mesenchymal stem cells described above is not particularly limited, and a known preservative solution composition can be appropriately used. ..
- the preservation solution may contain an infusion solution, a cryoprotectant, albumin and the like.
- the infusion solution examples include Ringer's bicarbonate solution, but the infusion solution is not limited to this.
- the bicarbonate Ringer's solution a commercially available one can be used, and for example, Bicarbon (registered trademark) infusion solution (Awai Pharma Co., Ltd.) can be preferably used.
- Bicarbon (registered trademark) infusion solution (Awai Pharma Co., Ltd.)
- One type of infusion solution may be used alone, or a plurality of types may be used in combination.
- the amount of the cryoprotectant in the preservation solution according to the embodiment of the present invention is more preferably 0.5% to 50% (v / v) with respect to the total amount of the preservation solution.
- the preservation solution according to the embodiment of the present invention may contain albumin in order to more preferably protect cells in the process of freezing and thawing.
- the concentration when albumin is added is more preferably 0.25% to 25% (v / v) with respect to the total amount of the preservation solution.
- synovial membrane-derived mesenchymal stem cells are suspended in the above-mentioned preservation solution.
- a method of suspension for example, it is preferable to put the preservation solution in a container that can be cryopreserved and suspend the mesenchymal stem cells in the preservation solution.
- the amount ratio of the preservation solution to the mesenchymal stem cells at the time of suspension is not particularly limited as long as it can be cryopreserved, but is, for example, about 500,000 cells / mL to 10 million cells / mL. With such an amount, mesenchymal stem cells can be sufficiently suspended in the preservation solution.
- the freezing temperature may be appropriately set to a temperature at which the mesenchymal stem cells freeze, and examples thereof include ⁇ 80 ° C. or lower, or -196 ° C. or lower.
- a temperature at which the mesenchymal stem cells freeze examples thereof include ⁇ 80 ° C. or lower, or -196 ° C. or lower.
- the method for producing a therapeutic preparation of the present embodiment includes a step of thawing the above-mentioned suspension and diluting the suspension so that the mesenchymal stem cells have a concentration suitable for administration.
- the cells may be thawed at a temperature that does not damage the cells, preferably 10 ° C. or higher and 45 ° C. or lower, and more preferably 20 ° C. or higher and 40 ° C. or lower. , 35 ° C or higher and 40 ° C or lower are more preferable.
- a hot water bath at 35 to 38 ° C. This is because it is rapid and has a higher cell recovery rate and survival rate.
- the thawed suspension is diluted with a diluted solution such as physiological saline or Ringer's solution.
- the diluent is not particularly limited as long as it can maintain the function of synovial membrane-derived mesenchymal stem cells.
- the dilution concentration may be appropriately adjusted so that the mesenchymal stem cells have a concentration suitable for administration.
- the dilution concentration is adjusted so that the number of mesenchymal stem cells is about 500,000 cells / mL to 3 million cells / mL. do it.
- One embodiment of the present invention may have the following configuration.
- a composition for treating central nervous system diseases which contains synovial-derived mesenchymal stem cells cultured in a serum-free medium.
- the central neurological disorder is at least one of Alzheimer's disease, vascular dementia, Parkinson's disease, Huntington's disease, multiple sclerosis and muscular atrophic lateral sclerosis, [1].
- a method for producing a composition for treating central nervous system diseases which comprises a step of culturing synovial membrane-derived mesenchymal stem cells in a serum-free medium.
- a method for producing a therapeutic formulation for central nervous system disease comprising a step of thawing and diluting the suspension so that the mesenchymal stem cells have a concentration suitable for administration.
- Example 1 Evaluation of synovial-derived mesenchymal stem cells for cerebral infarction.
- FIG. 1 shows an outline of the procedure of the evaluation method according to this embodiment.
- a cerebral infarction model rat was prepared, and mesenchymal stem cells (MSC) were administered immediately after cerebral ischemia reperfusion, and one day later, behavioral evaluation and histological evaluation were performed.
- MSC mesenchymal stem cells
- Mesenchymal stem cells from human synovial or bone marrow tissue are serum-free medium STK® 1 (TWOCELLS Co., Ltd.) or 10% fetal bovine serum. It was separated and cultured in the contained DMEM medium (Sigma-Aldorich).
- Mesenchymal stem cells of the synovial membrane separated in serum-free medium STK (registered trademark) 1 were seeded in serum-free medium STK (registered trademark) 2 (TWOCELLS Co., Ltd.) and separated in DMEM medium containing 10% bovine serum.
- the mesenchymal stem cells of the synovial or bone marrow were seeded in the same medium, and the mesenchymal stem cells were cultured for 10 to 15 days under the conditions of 37 ° C. and 5% CO 2 , respectively.
- a rat model of cerebral infarction was prepared (SPHPR-710-2 rat cerebral infarction model (Koizumi model)). Cerebral ischemia was performed by inserting an embolus toward the internal carotid artery of the rat and occluding the left middle cerebral artery. A cerebral infarction model rat was prepared by removing the embolus 120 minutes after cerebral ischemia and resuming blood flow.
- Example (A) synovial membrane-derived mesenchymal stem cells cultured in a serum-free medium were collected from the tail vein of a cerebral infarction model rat at a rate of 0.8 mL / min. A group administered over a minute was prepared (A-G2).
- Comparative Example (B) synovial membrane-derived or bone marrow-derived mesenchymal stem cells cultured in DMEM medium containing 10% fetal bovine serum were used in the tail of a cerebral infarction model rat at a rate of 0.8 mL / min for each.
- a group was prepared to be administered intravenously over 1 minute (B-G2 or B-G3).
- Example (A) and Comparative Example (B) as a negative control (NC), Sollacto (registered trademark) infusion solution (Terumo Corporation) containing no mesenchymal stem cells was used as a cerebral infarction model in the same manner as described above.
- a group administered to the tail vein of rats was prepared (A-G1 or B-G1).
- Example (A) and Comparative Example (B) as a positive control (PC), 0.5 mg / mg of FK-506 (tacrolimus, Astellas Pharma Inc.), which has been shown to reduce cerebral infarction lesions.
- a group was prepared in which kg was administered to the tail vein of a cerebral infarction model rat (A-G3 or B-G4).
- One day after administration of mesenchymal stem cells behavioral evaluation and histological evaluation were performed on the cerebral infarction model rat groups of Example (A) and Comparative Example (B), respectively.
- Example (A) The cerebral infarction model rat group of Example (A) and Comparative Example (B) were observed for neurological symptoms and evaluated behaviorally. For each individual, 0 to 12 for 5 items of (1) forelimb paralysis, (2) hindlimb paralysis, (3) rotational movement, (4) lateral resistance and (5) general condition (pathological condition: the higher the value, the worse) And the total of 5 items was evaluated as a neurological symptom score.
- forelimb paralysis the degree of flexion of the right forelimb when holding the rat's tail and lifting it about 10 cm from the floor is observed, and when there is no difference between the left and right forelimbs, 0 points and mild flexion. It was measured as 1 point when there was a presence, 2 points when there was a bending of about 90 degrees, and 3 points when it was impossible to move.
- hindlimb paralysis observe the force to restore the hindlimb when the rat's hindlimb is pulled at rest, 0 points when there is no difference in muscle strength between the left and right hindlimbs, and there is a difference in muscle strength between the left and right hindlimbs.
- the case was measured as 1 point, the case of becoming unnatural but restored by stimulation was measured as 2 points, and the case of becoming unnatural and unresponsive to the stimulus was measured as 3 points.
- (3) In the rotational movement observe the rotational movement with the rat's tail held and the front limbs attached to the floor, and point 0 when moving forward, mainly moving forward, but rotating clockwise.
- the case was measured as 1 point, the case of rotating mainly clockwise and moving forward was measured as 2 points, and the case of rotating only clockwise was measured as 3 points.
- Figure 2 shows the measurement results of the neurological symptom score.
- the statistical analysis of the neurological symptom score was performed using the Steel test, and in each analysis, the negative control was used as the control group, and the significance level was set to 5% on both sides.
- statistically significant differences are shown as "*: P ⁇ 0.05" and "**: P ⁇ 0.01".
- a statistical analysis of the neurological symptoms of rats was performed based on the measurement results shown in FIG. 2.
- the positive controls (A-G3 and B-G4) were statistically compared to the negative controls (A-G1 and B-G1).
- Significant (P ⁇ 0.05) improvement in neurological symptom score was observed. Therefore, it was shown that the condition of the neurological symptom score can evaluate the recovery of cerebral infarction behaviorally.
- A-G2 administered with synovial-derived mesenchymal stem cells cultured in serum-free medium showed a statistically significant (P ⁇ 0.01) improvement in neurological symptom score with respect to negative control. rice field.
- the total cerebral infarct lesion (mm 3 ) of the cerebral cortex and the basal ganglia was calculated from the product of the area of the cerebral infarction lesion in each cross section and the cross-sectional thickness (2 mm), and the total of these was taken as the total cerebral infarction lesion volume.
- Figure 3 shows the results of measuring the area of the total cerebral infarction lesion.
- the statistical analysis of total cerebral infarction was performed using Dunnett's test, and in all the analyzes, the negative control was used as the control group, and the significance level was 5% on both sides.
- statistically significant differences are shown as "*: P ⁇ 0.05" and "***: P ⁇ 0.001".
- mesenchymal stem cells derived from the synovial membrane cultured in a serum-free medium were realized when the mesenchymal stem cells cultured in a serum-containing medium were used. It has been shown to have a significantly higher (in other words, high enough to be available in clinical practice) effects on central nervous system diseases that cannot be achieved.
- Example 2 Evaluation of synovial-derived mesenchymal stem cells for spinal cord injury.
- FIG. 4 shows an outline of the procedure of the evaluation method according to this embodiment.
- a spinal cord injury model rat was prepared, mesenchymal stem cells (MSC) were administered the next day after the spinal cord injury, and hindlimb motor function was performed until the 4th week (28th day) after the spinal cord injury.
- MSC mesenchymal stem cells
- Example 2-1 Similar to [Example 1], synovial membrane-derived mesenchymal stem cells were cultured. Subsequently, as an example of central nervous system disease, a rat of a spinal cord injury model by a 50 mm weight drop method using MASCIS Impactor was prepared.
- BBB Basso-Beattie-Bresnahan scale
- FIG. 5 shows the measurement results of the hindlimb motor function evaluation.
- the statistical analysis of the BBB score was analyzed by the Kruskal-Wallis test method, and the statistical significance was examined, and a risk rate of less than 5% was considered to be significant.
- Example 2-2 Similar to [Example 1], synovial membrane-derived mesenchymal stem cells were cultured. Subsequently, as an example of central nervous system disease, a rat of a spinal cord injury model by a 50 mm weight drop method using MASCIS Impactor was prepared using a rat different from Experimental Example 2-1.
- FIG. 6 shows the measurement results of the hindlimb motor function evaluation.
- the statistical analysis of the BBB score was analyzed by the t-test method, and the statistical significance was examined. When the p-value was less than 0.10, it was considered to have a significant tendency. In the measurement result of FIG. 6, the statistically significant tendency is shown as " ⁇ : P ⁇ 0.10".
- the present invention can provide a safer and more useful therapeutic composition for central nervous system disease using mesenchymal stem cells, it is an object of the present invention to recover and regenerate central nervous system disease using mesenchymal stem cells. It can be suitably used for medical treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明の一実施形態にかかる中枢神経疾患の治療用組成物の製造方法(以下、「本実施形態の製造方法」ともいう。)は、無血清培地中で滑膜由来の間葉系幹細胞を培養する工程を含む方法である。
本実施形態の製造方法において、滑膜由来の間葉系幹細胞を培養する無血清培地の組成は特に限定されず、公知の無血清培地の組成を適宜使用することができる。無血清培地を構成するための基礎培地は、公知の哺乳動物細胞用培地であれば特に限定されず、好ましい基礎培地としては、例えば、Ham’s F12培地、DMEM培地、RPMI-1640培地、MCDB培地等が挙げられる。これらの基礎培地は、単独で使用されても、複数を混合して使用されてもよい。一実施形態において、無血清培地を構成するための基礎培地は、MCDBとDMEMとを1:1の比率で混合した培地が好ましい。
本実施形態の製造方法では、上述した無血清培地に、ヒト等の動物組織または細胞から従来公知の方法により単離された滑膜由来の間葉系幹細胞を播種し培養する。培養条件として、例えば、培地1mLに対して1~500mgの組織片(間葉系幹細胞を含む)から分離した滑膜由来の間葉系幹細胞を播種することが好ましく、培養温度は37℃±1℃、かつ5%CO2下であることが好ましい。
本発明の一実施形態にかかる中枢神経疾患の治療用組成物(以下「本実施形態の治療用組成物」という。)は、無血清培地中で培養された滑膜由来の間葉系幹細胞を含有している。
本発明の一実施形態にかかる中枢神経疾患の治療用製剤の製造方法(本実施形態の治療用製剤の製造方法)は、無血清培地中で培養された滑膜由来の間葉系幹細胞を、凍結のための保存液に懸濁し、得られた懸濁液を凍結する凍結保存工程と、前記懸濁液を融解し、前記間葉系幹細胞が投与に適した濃度となるように、前記懸濁液を希釈する工程と、を含む。
(脳梗塞に対する滑膜由来の間葉系幹細胞の有効性評価)
無血清培地中で培養された滑膜由来の間葉系幹細胞の移植による脳梗塞の後遺症の改善に係る検討を行った。
実施例(A)および比較例(B)の脳梗塞モデルラット群について、神経症状の観察を行い、行動学的評価を行った。個体別に、(1)前肢麻痺、(2)後肢麻痺、(3)回転運動、(4)体側面抵抗性および(5)一般状態の5項目について0~12(病態:数値が高いほど悪い)でスコア化し、5項目の合計を神経症状スコアとして評価した。
続いて、実施例(A)および比較例(B)の脳梗塞モデルラット群について、脳梗塞巣の容積を測定し、組織学的評価を行った。神経症状の観察後、全脳を摘出し、ラット用ブレインマトリックスを用いて切片を作製した。各切片を2% 2,3,5-Triphenyltetrazolium chloride(TTC)を含む生理食塩液中で染色し、脳梗塞巣容積定量用画像をスキャナーで取り込んだ。当該画像を、OsiriX version 8.0.2(Pixmeo SARL)にてTTC非染色部分を脳梗塞巣としてマーキングし、面積を測定した。面積の測定は、大脳皮質および基底核について実施した。各断面の脳梗塞巣の面積と断面厚(2mm)の積から大脳皮質および基底核の総脳梗塞巣(mm3)を算出し、これらの合計を総脳梗塞巣容積とした。
(脊髄損傷に対する滑膜由来の間葉系幹細胞の有効性評価)
無血清培地中で培養された滑膜由来の間葉系幹細胞の移植による脊髄損傷の後遺症の改善に係る検討を行った。
〔実施例1〕と同様に、滑膜由来の間葉系幹細胞を培養した。続いて、中枢神経疾患の一例として、MASCIS Impactorを用いた50mm重錘落下法による脊髄損傷モデルのラットを作製した。
図5に後肢運動機能評価の測定結果を示す。なお、BBBスコアの統計解析は、Kruskal-Wallisの検定法で解析し、統計学的有意性の検討を行い、危険率5%未満を有意差ありとした。
〔実施例1〕と同様に、滑膜由来の間葉系幹細胞を培養した。続いて、中枢神経疾患の一例として、実験例2-1とは異なるラットを用いて、MASCIS Impactorを用いた50mm重錘落下法による脊髄損傷モデルのラットを作製した。
図6に後肢運動機能評価の測定結果を示す。なお、BBBスコアの統計解析は、t検定法で解析し、統計学的有意性の検討を行った。p値が0.10未満の場合を有意傾向ありとした。図6の測定結果において、統計的な有意傾向を、「†:P<0.10」として示す。
Claims (5)
- 無血清培地中で培養された滑膜由来の間葉系幹細胞を含有している、中枢神経疾患の治療用組成物。
- 前記中枢神経疾患は、脳梗塞、脳出血、頭部外傷および脊髄損傷の、少なくともいずれか1つである、請求項1に記載の中枢神経疾患の治療用組成物。
- 前記中枢神経疾患は、アルツハイマー病、脳血管性認知症、パーキンソン病、ハンチントン病、多発性硬化症および筋萎縮性側索硬化症の、少なくともいずれか1つである、請求項1に記載の中枢神経疾患の治療用組成物。
- 無血清培地中で滑膜由来の間葉系幹細胞を培養する工程を含む、中枢神経疾患の治療用組成物の製造方法。
- 無血清培地中で培養された滑膜由来の間葉系幹細胞を、凍結のための保存液に懸濁し、得られた懸濁液を凍結する凍結保存工程と、
前記懸濁液を融解し、前記間葉系幹細胞が投与に適した濃度となるように、前記懸濁液を希釈する工程と、を含む、中枢神経疾患の治療用製剤の製造方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/011,367 US20230302055A1 (en) | 2020-09-03 | 2021-08-04 | Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases |
AU2021337035A AU2021337035A1 (en) | 2020-09-03 | 2021-08-04 | Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases |
CN202180043870.5A CN115867296A (zh) | 2020-09-03 | 2021-08-04 | 中枢神经疾病治疗用组合物、中枢神经疾病治疗用组合物的制造方法以及中枢神经疾病治疗用制剂的制造方法 |
EP21864035.7A EP4209223A1 (en) | 2020-09-03 | 2021-08-04 | Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases |
KR1020237009736A KR20230054445A (ko) | 2020-09-03 | 2021-08-04 | 중추신경 질환의 치료용 조성물, 중추신경 질환의 치료용 조성물의 제조 방법 및 중추신경 질환의 치료용 제재의 제조 방법 |
JP2022546179A JP7444267B2 (ja) | 2020-09-03 | 2021-08-04 | 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020148528 | 2020-09-03 | ||
JP2020-148528 | 2020-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022049977A1 true WO2022049977A1 (ja) | 2022-03-10 |
Family
ID=80492038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/028948 WO2022049977A1 (ja) | 2020-09-03 | 2021-08-04 | 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230302055A1 (ja) |
EP (1) | EP4209223A1 (ja) |
JP (1) | JP7444267B2 (ja) |
KR (1) | KR20230054445A (ja) |
CN (1) | CN115867296A (ja) |
AU (1) | AU2021337035A1 (ja) |
WO (1) | WO2022049977A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007176A1 (ja) * | 2003-06-27 | 2005-01-27 | Renomedix Institute Inc. | 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬 |
WO2007080919A1 (ja) | 2006-01-13 | 2007-07-19 | Japan Science And Technology Agency | 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 |
WO2009034708A1 (ja) * | 2007-09-11 | 2009-03-19 | Sapporo Medical University | 細胞増殖方法ならびに組織の修復および再生のための医薬 |
WO2011111787A1 (ja) | 2010-03-10 | 2011-09-15 | 株式会社ツーセル | 間葉系幹細胞を含む細胞製剤及びその製造方法 |
JP2012157263A (ja) * | 2011-01-31 | 2012-08-23 | Seems Inc | アルツハイマー病治療に向けたヒト脂肪組織由来間葉系幹細胞 |
WO2015016357A1 (ja) | 2013-08-01 | 2015-02-05 | 株式会社ツーセル | 軟骨損傷治療剤及びその製造方法 |
WO2018123968A1 (ja) * | 2016-12-28 | 2018-07-05 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
-
2021
- 2021-08-04 WO PCT/JP2021/028948 patent/WO2022049977A1/ja unknown
- 2021-08-04 KR KR1020237009736A patent/KR20230054445A/ko unknown
- 2021-08-04 JP JP2022546179A patent/JP7444267B2/ja active Active
- 2021-08-04 EP EP21864035.7A patent/EP4209223A1/en active Pending
- 2021-08-04 AU AU2021337035A patent/AU2021337035A1/en active Pending
- 2021-08-04 US US18/011,367 patent/US20230302055A1/en active Pending
- 2021-08-04 CN CN202180043870.5A patent/CN115867296A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007176A1 (ja) * | 2003-06-27 | 2005-01-27 | Renomedix Institute Inc. | 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬 |
WO2007080919A1 (ja) | 2006-01-13 | 2007-07-19 | Japan Science And Technology Agency | 動物細胞を無血清培養するための培地用添加剤、キット及びこれらの利用 |
WO2009034708A1 (ja) * | 2007-09-11 | 2009-03-19 | Sapporo Medical University | 細胞増殖方法ならびに組織の修復および再生のための医薬 |
WO2011111787A1 (ja) | 2010-03-10 | 2011-09-15 | 株式会社ツーセル | 間葉系幹細胞を含む細胞製剤及びその製造方法 |
JP2012157263A (ja) * | 2011-01-31 | 2012-08-23 | Seems Inc | アルツハイマー病治療に向けたヒト脂肪組織由来間葉系幹細胞 |
WO2015016357A1 (ja) | 2013-08-01 | 2015-02-05 | 株式会社ツーセル | 軟骨損傷治療剤及びその製造方法 |
WO2018123968A1 (ja) * | 2016-12-28 | 2018-07-05 | 株式会社ツーセル | 生体組織損傷の修復剤および当該修復剤の製造方法 |
Non-Patent Citations (3)
Title |
---|
BASSO ET AL.: "A sensitive and reliable locomotor rating scale for open field testing in rats", J. NEUROTRAUMA, vol. 12, 1995, pages 1 - 21, XP009036806 |
JINCHANG SHAO, SHINICHI HASEGAWA, YUKIO KATO, TSUJI KOICHIRO: "Development of chemically defined serum-free media: SKT series (STK1, STK2, STK3) for human mesenchymal stem cell", THE CHEMICAL TIMES, vol. 2020, no. 2, 1 April 2020 (2020-04-01), Japan , pages 17 - 22, XP009534946, ISSN: 0285-2446 * |
NISHINA, HIROSHI: "Development of serum-free cell culture method of human dermal stem cells and transplant indication to spinal cord injury model in rats", JAPANESE JOURNAL OF TRANSPLANTATION, vol. 45, no. 3, 1 January 2010 (2010-01-01), JP , pages 301 - 302, XP009534945, ISSN: 0578-7947 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022049977A1 (ja) | 2022-03-10 |
EP4209223A1 (en) | 2023-07-12 |
AU2021337035A1 (en) | 2023-03-30 |
JP7444267B2 (ja) | 2024-03-06 |
CN115867296A (zh) | 2023-03-28 |
US20230302055A1 (en) | 2023-09-28 |
KR20230054445A (ko) | 2023-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7113430B2 (ja) | 生体組織損傷の修復剤および当該修復剤の製造方法 | |
JP7126703B2 (ja) | 臍帯由来細胞を含む脳障害の治療剤 | |
US20100196329A1 (en) | Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue | |
KR20180016720A (ko) | 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물 | |
KR101520536B1 (ko) | 편도유래 줄기세포의 간세포로의 분화 방법 및 편도유래 줄기세포를 포함하는 간 기능 손상 치료용 세포치료제 조성물 | |
Linon et al. | Engraftment of autologous bone marrow cells into the injured cranial cruciate ligament in dogs | |
JP6141522B2 (ja) | 静脈投与用幹細胞組成物 | |
US20170105406A1 (en) | Composition for improving stability of stem cells | |
WO2022049977A1 (ja) | 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法 | |
JP7506905B2 (ja) | 添加剤 | |
JPWO2019026910A1 (ja) | 凍結保存用組成物、凍結保存物の製造方法、細胞製剤、細胞製剤の製造方法、凍結保存用キット | |
WO2012115298A1 (ko) | 양수 유래 줄기세포를 함유하는 요실금 치료제 | |
WO2017141831A1 (ja) | 脂肪組織由来間質細胞を含む虚血性疾患治療剤およびその製造方法 | |
WO2021060460A1 (ja) | 生体組織損傷の修復剤の製造方法および生体組織損傷の修復剤 | |
WO2024063020A1 (ja) | 椎間板治療剤 | |
WO2016076434A1 (ja) | 歯髄由来多能性幹細胞を含有する筋ジストロフィー治療剤 | |
US20230321156A1 (en) | Cell preparation for use in suppressing muscle mass loss | |
EP3330369B1 (en) | Capillary vessel-derived stem cells, use of the same, and, method for producing the same | |
Umezawa | Prospects of Regenerative Medicine Using Mesenchymal Stem Cells | |
Tierney | The effect of peroneal nerve relocation on skeletal muscle regeneration within an extracellular matrix seeded with mesenchymal stem cell populations derived from bone marrow and adipose tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21864035 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022546179 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237009736 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021337035 Country of ref document: AU Date of ref document: 20210804 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021864035 Country of ref document: EP Effective date: 20230403 |